|
|
Profile
|
Delegates :
Hideaki Ogasawara |
|
Incorporated :
September 13 , 2018 |
Paid in Capital :
5 Million yen |
Employees :
2 人 |
Address :
#403, Todaimae HiRAKU GATE 2-3-10, Mukogaoka, Bunkyo City TOKYO
〒1130023
|
TEL/FAX :
+81 3 3868 2260‬ / |
URL：
https://www.tansobio.com/ |
Attachment :
 leaflet_tanso_en.pdf [ 842.9KiB ] |
Mission/Background :
Researchers at the Faculty of Medicine, The University of Tokyo have developed an extraordinarily sensitive, comprehensive, and specific cell-based assay for GPCRs. Tanso Biosciences is the academic spin-off to apply their innovation and revolutionize drug discovery.
With its assay platform, Tanso Biosciences contributes to promoting human health by expanding frontiers, accelerating research, and reducing risks of drug development.
Our business model consists of two pillars.
1. Contract services
We provide exhaustive on-target and off-target screening services for pharmaceuticals and biotechs.
2. Drug discovery
We make best use of our reliable one-fits-all GPCR functional assay method and target GPCRs that have historically been difficult with existing methods, namely, orphan receptors, G12/13-coupled receptors, and Gi/o-coupled receptors. |
|
Technology & Business
|
Key features
*Highly sensitive and specific
*Reliable in the screening of any human GPCRs regardless of Gα protein subtypes (Gs, Gi/o, Gq, G12/13); validated with >99% (216 out of 218) of non-orphan GPCRs.
*Can screen for agonists, antagonists, inverse agonists, PAMs, and NAMs
*Handy, quick, and exceptionally cost-effective
Uses
*On-target and off-target screening for drug discovery
*Profiling of seed/hit/lead compounds
*Strategy development
*In-licensing assessment
*Repositioning
*Preclinical off-target screening
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Comprehensive functional assay for >300 human GPCRs
|
Service/Marketing
|
We provide on-target and off-target screening services for pharmaceuticals, biotechs, and manufacturers in related industries
|
To develop partnership with pharmaceuticals and biotechs
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
International patent for the assay method filed in July, 2019.
Marketing campaign launched in August.
First joint research project to begin in September.
|
|
Hot news
|
International patent filed in July, 2019. Negotiation under NDA ongoing with several pharmaceuticals and biotechs.
|
|
Alliance strategy
|
We conduct GPCR functional assays on a contract basis. We also seek opportunities to collaborate with pharmaceuticals and biotechs in drug research.
|
|
|